1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-8 of 8 (Search time: 0.001 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2009A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALLTojo, A.; Usuki, K.; Urabe, A.; Maeda, Y.; Kobayashi, Y.; Jinnai, I.; Ohyashiki, K.; Nishimura, M.; Kawaguchi, T.; Tanaka, H.; Miyamura, K.; Miyazaki, Y.; Hughes, T.; Branford, S.; Okamoto, S.; Ishikawa, J.; Okada, M.; Usui, N.; Tanii, H.; Amagasaki, T.; et al.
2009Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplificationRoss, D.; Schafranek, L.; Hughes, T.; Nicola, M.; Branford, S.; Score, J.
2009Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaHochhaus, A.; O'Brien, S.; Guilhot, F.; Druker, B.; Branford, S.; Foroni, L.; Goldman, J.; Muller, M.; Radich, J.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T.; Larson, R.
2009Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive valueHochhaus, A.; Muller, M.; Radich, J.; Branford, S.; Kantarjian, H.; Hanfstein, B.; Rousselot, P.; Kim, D.; Lipton, J.; Bleickhardt, E.; Lambert, A.; Hughes, T.
2009Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phaseHughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, J.; Muller, M.; Martinelli, G.; Cortes, J.; Beppu, L.; Gottardi, E.; Dongho, K.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A.
2009Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Branford, S.; Vaz de Melo, J.; Hughes, T.
2009Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMuller, M.; Cortes, J.; Kim, D.; Druker, B.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T.; Radich, J.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A.
2009Measuring minimal residual disease in chronic myeloid leukemia: Fluorescence in situ hybridization and polymerase chain reactionHughes, T.; Branford, S.

Discover